Potent strategy to inhibit HIV-1 by binding both gp120 and gp41

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 264-275

  Kagiampakis, Ioannis ^b   Gharibi, Arbi ^a   Mankowski, Marie K ^c   Snyder, Beth A ^c   Ptak, Roger G ^c   Alatas, Kristabelle ^a   LiWang, Patricia J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 BINDING PEPTIDE C37; GRIFFITHSIN; GRIFFITHSIN GLYCOPROTEIN GP41 BINDING PEPTIDE C37; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE CD4M33; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; COVALENT BOND; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN;

ALGAL PROTEINS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; LECTINS; PEPTIDES; PROTEIN BINDING;

EID: 78650647228     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00376-10     Document Type: Article

References (65)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
3. Chackerian, B., E. M. Long, P. A. Luciw, and J. Overbaugh. 1997. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71:3932-3939.
4. Champagne, K., A. Shishido, and M. J. Root. 2009. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J. Biol. Chem. 284:3619-3627.
5. Chan, D. C., C. T. Chutkowski, and P. S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95:15613-15617.
6. Chen, B., E. M. Vogan, H. Gong, J. J. Skehel, D. C. Wiley, and S. C. Harrison. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
7. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
8. Ciminale, V., B. K. Felber, M. Campbell, and G. N. Pavlakis. 1990. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res. Hum. Retroviruses 6:1281-1287.
9. Clore, G. M., and A. M. Gronenborn. 1997. NMR structures of proteins and protein complexes beyond 20,000 Mr. Nat. Struct. Biol. 4(Suppl.):849-853.
10. Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
11. Delaglio, F., S. Grzesiek, G. W. Vuister, G. Hu, J. Pfeifer, and A. Bax. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6:277-293.
12. Deng, Y., Q. Zheng, T. J. Ketas, J. P. Moore, and M. Lu. 2007. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 46: 4360-4369.
13. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
14. Dey, B., C. S. Del Castillo, and E. A. Berger. 2003. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 77:2859-2865.
15. Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
16. Emau, P., B. Tian, B. R. O'Keefe, T. Mori, J. B. McMahon, K. E. Palmer, Y. Jiang, G. Bekele, and C. C. Tsai. 2007. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36:244-253.
17. Frank, M. K., G. M. Clore, and A. M. Gronenborn. 1995. Structural and dynamic characterization of the urea denatured state of the immunoglobulin binding domain of streptococcal protein G by multidimensional heteronuclear NMR spectroscopy. Protein Sci. 4:2605-2615.
18. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
19. Gendelman, H. E., L. M. Baca, C. A. Kubrak, P. Genis, S. Burrous, R. M. Friedman, D. Jacobs, and M. S. Meltzer. 1992. Induction of IFN-alpha; in peripheral blood mononuclear cells by HIV-infected monocytes. Restricted antiviral activity of the HIV-induced IFN. J. Immunol. 148:422-429.
20. Gendelman, H. E., J. M. Orenstein, L. M. Baca, B. Weiser, H. Burger, D. C. Kalter, and M. S. Meltzer. 1989. The macrophage in the persistence and pathogenesis of HIV infection. AIDS 3:475-495.
21. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
22. Giomarelli, B., K. M. Schumacher, T. E. Taylor, R. C. Sowder II, J. L. Hartley, J. B. McMahon, and T. Mori. 2006. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture. Protein Expr. Purif. 47:194-202.
23. Hart, C. E., and T. Evans-Strickfaden. 2007. HIV-1 entry inhibitors as microbicides, p. 99-117. In J. D. Reeves and C. A. Derdeyn (ed.), Entry inhibitors in HIV therapy. Birkhäuser Verlag, Basel, Switzerland.
24. Jacobson, J. M., R. J. Israel, I. Lowy, N. A. Ostrow, L. S. Vassilatos, M.Barish, D. N. Tran, B. M. Sullivan, T. J. Ketas, T. J. O'Neill, K. A. Nagashima, W. Huang, C. J. Petropoulos, J. P. Moore, P. J. Maddon, and W. C. Olson. 2004. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48:423-429.
25. Jekle, A., E. Chow, E. Kopetzki, C. Ji, M. J. Yan, R. Nguyen, S. Sankuratri, N. Cammack, and G. Heilek. 2009. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res. 83:257-266.
26. Ji, C., E. Kopetzki, A. Jekle, K. G. Stubenrauch, X. Liu, J. Zhang, E. Rao, T. Schlothauer, S. Fischer, N. Cammack, G. Heilek, S. Ries, and S. Sankuratri. 2009. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J. Biol. Chem. 284:5175-5185.
27. Jin, H., I. Kagiampakis, P. Li, and P. J. LiWang. 2010. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES. Proteins 78:295-308.
28. Kahle, K. M., H. K. Steger, and M. J. Root. 2009. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 5:e1000674.
29. Klein, J. S., P. N. Gnanapragasam, R. P. Galimidi, C. P. Foglesong, A. P. West, Jr., and P. J. Bjorkman. 2009. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. U. S. A. 106:7385-7390.
30. Kopetzki, E., A. Jekle, C. Ji, E. Rao, J. Zhang, S. Fischer, N. Cammack, S. Sankuratri, and G. Heilek. 2008. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol. J. 5:56.
31. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
32. Lackman-Smith, C., C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R. G. Ptak, R. W. Buckheit, Jr., K. M. Watson, J. E. Cummins, Jr., and B. E. Sanders-Beer. 2008. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52:1768-1781.
33. Liu, S., H. Lu, J. Niu, Y. Xu, S. Wu, and S. Jiang. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280: 11259-11273.
34. LiWang, A. C., J. J. Cao, H. Zheng, Z. Lu, S. C. Peiper, and P. J. LiWang. 1999. Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage inflammatory protein-II (vMIP-II) reveals a fully monomeric protein. Biochemistry 38:442-453.
35. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
36. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
37. Reference deleted.
38. Martin, L., F. Stricher, D. Misse, F. Sironi, M. Pugniere, P. Barthe, R. Prado-Gotor, I. Freulon, X. Magne, C. Roumestand, A. Menez, P. Lusso, F. Veas, and C. Vita. 2003. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21:71-76.
39. Miyauchi, K., Y. Kim, O. Latinovic, V. Morozov, and G. B. Melikyan. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433-444.
40. Mori, T., B. R. O'Keefe, R. C. Sowder II, S. Bringans, R. Gardella, S. Berg, P. Cochran, J. A. Turpin, R. W. Buckheit, Jr., J. B. McMahon, and M. R. Boyd. 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353.
41. O'Keefe, B. R., F. Vojdani, V. Buffa, R. J. Shattock, D. C. Montefiori, J. Bakke, J. Mirsalis, A. L. d'Andrea, S. D. Hume, B. Bratcher, C. J. Saucedo, J. B. McMahon, G. P. Pogue, and K. E. Palmer. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
42. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
43. Pleskoff, O., C. Treboute, A. Brelot, N. Heveker, M. Seman, and M. Alizon. 1997. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276:1874-1878.
44. Popovic, M., S. Gartner, E. Read-Connole, B. Beaver, and M. Reitz. 1989. Cell tropism and expression of HIV-1 isolated in natural targets, p. 219-224. In L. Valette and M. Girard (ed.), Retroviruses of human AIDS and related animal diseases. Pasteur Vaccins, Marnes-La-Coquette, France.
45. Popovic, M., E. Read-Connole, and R. C. Gallo. 1984. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet ii:1472-1473.
46. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500. (Pubitemid 14134740)
47. Poveda, E., V. Briz, and V. Soriano. 2005. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 7:139-147.
48. Promega. March 2009, revision date. Technical manual: ProFection mammalian transfection system. Promega, Madison, WI. http://www.promega.com/tbs/ tm012/tm012.pdf.
49. Ptak, R. G., P. A. Gallay, D. Jochmans, A. P. Halestrap, U. T. Ruegg, L. A. Pallansch, M. D. Bobardt, M. P. de Bethune, J. Neyts, E. De Clercq, J. M. Dumont, P. Scalfaro, K. Besseghir, R. M. Wenger, and B. Rosenwirth. 2008. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52:1302-1317.
50. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284. (Pubitemid 15151982)
51. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.
52. Root, M. J., and H. K. Steger. 2004. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 10:1805-1825.
53. Sattentau, Q. J., J. P. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:7383-7393.
54. Shu, W., J. Liu, H. Ji, L. Radigen, S. Jiang, and M. Lu. 2000. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39:1634-1642.
55. Stoddart, C. A., G. Nault, S. A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellomo, V. Paradis, P. Liscourt, A. Lobach, M. E. Rivard, R. G. Ptak, M. K. Mankowski, D. Bridon, and O. Quraishi. 2008. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283:34045-34052.
56. Sullivan, N., Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski. 1998. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:4694-4703.
57. Takeuchi, Y., M. O. McClure, and M. Pizzato. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
58. UNAIDS. 2008. 2008 report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report.asp.
59. Wang, H. G., R. E. Williams, and P. F. Lin. 2004. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr. Pharm. Des. 10:1785-1793.
60. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
61. Westervelt, P., H. E. Gendelman, and L. Ratner. 1991. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc. Natl. Acad. Sci. U. S. A. 88:3097-3101.
62. Wishart, D. S., C. G. Bigam, J. Yao, F. Abildgaard, H. J. Dyson, E. Oldfield, J. L. Markley, and B. D. Sykes. 1995. 1H, 13C, 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6:135-140.
63. Ziółkowska, N. E., B. R. O'Keefe, T. Mori, C. Zhu, B. Giomarelli, F. Vojdani, K. E. Palmer, J. B. McMahon, and A. Wlodawer. 2006. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14:1127-1135.
64. Ziółkowska, N. E., S. R. Shenoy, B. R. O'Keefe, J. B. McMahon, K. E. Palmer, R. A. Dwek, M. R. Wormald, and A. Wlodawer. 2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins 67:661-670.
65. Ziółkowska, N. E., S. R. Shenoy, B. R. O'Keefe, and A. Wlodawer. 2007. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine. Protein Sci. 16:1485-1489.